

CENTRO DE IMAGEM DIAGNÓSTICOS S.A.

Corporate Taxpayer's ID (CNPJ/MF): 42.771.949/0001-35

NOTICE TO THE MARKET

CENTRO DE IMAGEM DIAGNÓSTICOS S.A. ("**Company**" or "**Alliar**"), pursuant to Instruction 358 of the Brazilian Securities and Exchange Commission ("CVM"), of January 3, 2002, as amended, hereby informs that it has received a questioning by B3 S.A. – Brasil, Bolsa, Balcão ("**B3**") through letter 779/2021-SLS ("**Official Letter**"), with the following content:

"May 27, 2021

779/2021-SLS

Centro De Imagem Diagnósticos S.A.

Attention to Gabriel Bouzada

Rozenberg, Investor Relations Officer

Re: Request for clarification on atypical fluctuation

Dear Sir,

Given the recent fluctuations in the price of the company's securities, the number of trades and trading volume, as shown below, we hereby request you to inform, **by May 28, 2021**, if you are aware of any fact that can justify such fluctuation.

Common Shares									
Prices (R\$ per share)									
Date	Opening	Minimum	Maximum	Average	Closing	Fluctuation (%)	No. of trades	Quantity	Volume (R\$)
5/14/2021	9.25	9.16	10.04	9.69	9.98	13.02	7,697	3,456,400	33,475,646.00
5/17/2021	9.90	9.67	10.13	9.87	9.95	-0.30	4,242	1,280,100	12,630,570.00
5/18/2021	9.99	9.96	10.37	10.20	10.36	4.12	4,308	1,433,700	14,621,265.00
5/19/2021	10.29	10.16	10.94	10.61	10.86	4.82	5,074	2,165,400	22,964,280.00
5/20/2021	10.89	10.83	11.90	11.38	11.51	5.98	7,446	3,359,100	38,220,030.00
5/21/2021	11.47	11.13	11.85	11.47	11.19	-2.78	3,446	1,324,800	15,199,379.00
5/24/2021	11.27	10.44	11.32	10.81	10.55	-5.71	4,985	2,189,400	23,658,632.00
5/25/2021	10.62	10.30	11.28	10.82	10.97	3.98	5,478	1,654,800	17,911,935.00
5/26/2021	11.05	10.76	11.20	10.96	10.78	-1.73	4,755	1,501,700	16,453,727.00
5/27/2021*	10.70	10.60	11.90	11.58	11.90	10.39	8,614	4,484,300	51,931,055.00

*Last updated at 5:25 p.m."

In response to the questioning transcribed above, the Company informs that the number of trades, the trading volumes and the referred fluctuations mentioned in the Official Letter are primarily due to (i) the Company's positive result in the first quarter of 2021, released on May 13, 2021, when historical revenue and net income were reported, and (ii) the disclosure of the verticalization plan of the Company's Clinical Analysis operation, through the creation of its own Technical Operational Center (NTO), already informed to the market through a material fact dated May 13, 2021. The above-mentioned conditions, combined with the historical low liquidity of the Company's shares, led to positive and negative fluctuations, which are not normal to the Company's usual historical standards.

After having duly inquired its managers and controlling shareholder, in accordance with article 4 of CVM Instruction 358, the Company clarifies that there is no undisclosed material act or fact that justifies the atypical changes of its common shares on the aforementioned dates.

In view of the above and believing to have clarified the questionings presented by B3, the Company is available to provide any further clarifications that may be necessary.

Gabriel Rozenberg

Investor Relations Officer